Hrvatske smjernice za farmakološko liječenje šećerne bolesti tipa 2 [Croatian guidelines for the pharmacotherapy of type 2 diabetes]

Rahelić, Dario and Altabas, Velimir and Bakula, Miro and Balić, Stjepan and Balint, Ines and Bergman Marković, Biserka and Bičanić, Nenad and Bjelinski, Igor and Božikov, Velimir and Canecki Varžić, Silvija and Car, Nikica and Cigrovski Berković, Maja and Crnčević Orlić, Željka and Deškin, Marin and Drvodelić Šunić, Ema and Gojo Tomić, Nives and Goldoni, Vesna and Gradišer, Marina and Herman Mahečić, Davorka and Jandrić Balen, Marica and Jurišić Eržen, Dubravka and Klobučar Majanović, Sanja and Kokić, Slaven and Krnić, Mladen and Kruljac, Ivan and Liberati-Čižmek, Ana-Marija and Lukšić, Martina and Marušić, Srećko and Matić, Tomas and Metelko, Željko and Mirošević, Gorana and Mlinarić Vrbica, Sanja and Pavlić Renar, Ivana and Petric, Dragomir and Prašek, Manja and Prpić-Križevac, Ivana and Radman, Maja and Soldo, Dragan and Šarić, Tereza and Tešanović, Sandi and Tičinović Kurir, Tina and Turk Wensveen, Tamara and Vrca Botica, Marija and Vrkljan, Milan and Zjačić Rotkvić, Vanja and Zorić, Čedomir and Krznarić, Željko (2016) Hrvatske smjernice za farmakološko liječenje šećerne bolesti tipa 2 [Croatian guidelines for the pharmacotherapy of type 2 diabetes]. Liječnički vjesnik, 138 (1-2). pp. 1-21. ISSN 0024-3477

PDF Download (4MB)

Abstract

Introduction: The Croatian Association for Diabetes and Metabolic Disorders of the Croatian Medical Association has issued in 2011 the first national guidelines for the nutrition, education, self-control, and pharmacotherapy of diabetes type 2. According to the increased number of available medicines and new evidence related to the effectiveness and safety of medicines already involved in the therapy there was a need for update of the existing guidelines for the pharmacotherapy of type 2 diabetes in the Republic of Croatia. Participants: as co-authors of the Guidelines there are listed all members of the Croatian Association for Diabetes and Metabolic Diseases, as well as other representatives of professional societies within the Croatian Medical Association, who have contributed with comments and suggestions to the development of the Guidelines. Evidence: These guidelines are evidence-based, according to the GRADE system (eng. Grading of Recommendations, Assessment, Development and Evaluation), which describes the level of evidence and strength of recommendations. Conclusions: An individual patient approach based on physiological principles in blood glucose control is essential for diabetes' patients management. Glycemic targets and selection of the pharmacological agents should be tailored to the patient, taking into account the age, duration of disease, life expectancy, risk of hypoglyce- mia, comorbidities, developed vascular and other complications as well as other factors. Because of all this, is of national interest to have a practical, rational and applicable guidelines for the pharmacotherapy of type 2 diabetes.

Abstract in Croatian

Uvod: Hrvatsko društvo za dijabetes i bolesti metabolizma Hrvatskoga liječničkog zbora izradilo je 2011. godine prve nacionalne smjernice o prehrani, edukaciji i samokontroli te farmakološkom liječenju šećerne bolesti tipa 2. Sukladno povećanom broju dostupnih lijekova te novim spoznajama o učinkovitosti i sigurnosti primjene već uključenih lijekova, pokazala se potreba za obnovom postojećih smjernica za farmakološko liječenje šećerne bolesti tipa 2 u Republici ­Hrvatskoj. Sudionici: Kao koautori Smjernica navedeni su svi članovi Hrvatskog društva za dijabetes i bolesti metabolizma Hrvatskoga liječničkog zbora, kao i ostalih uključenih stručnih društava, koji su svojim komentarima i prijedlozima pridonijeli izradi Smjernica. Dokazi: Ove su Smjernice utemeljene na dokazima, prema sustavu GRADE (engl. Grading of Recommendations, Assessment, Development and Evaluation) koji uz razinu dokaza opisuje i snagu preporuke. Zaključci: Individualan pristup temeljen na fiziološkim principima regulacije glikemije nuždan je u liječenju osoba sa šećernom bolesti. Ciljeve liječenja i odabir medikamentne terapije treba prilagoditi oboljeloj osobi, uzimajući u obzir životnu dob, trajanje bolesti, očekivano trajanje života, rizik od hipoglikemije, komorbiditete, razvijene vaskularne i ostale komplikacije, kao i ostale čimbenike. Zbog svega navedenoga od nacionalnog je interesa imati praktične, racionalne i provedive smjernice za farmakološko liječenje šećerne bolesti tipa 2.

Actions (login required)

View Item

Downloads